Ginkgo bioworks and novo nordisk expand alliance to collaborate across r&d value chain

Boston , april 10, 2024 /prnewswire/ -- ginkgo bioworks (nyse: dna), which is developing the leading platform for cell programming and biosecurity, today announced the expansion of its strategic partnership with global healthcare leader novo nordisk under a framework agreement that initially is contemplated to run over five years.  novo nordisk and ginkgo have created a flexible and scalable new model for their r&d partnership.
DNA Ratings Summary
DNA Quant Ranking